David C. Krempa

David C. Krempa

Chief Business OfficeratEton Pharmaceuticals· In proxies 2022–2025

Pay in FY2025+5% from the year before · Eton Pharmaceuticals stock +27.0% the same year

David C. Krempa was paid $1.4M in FY2025 (Dec), up 5%. Eton Pharmaceuticals stock rose 27.0% that year.

Pay$100 in the stock at the end of FY21 → $254
Pay is from the Summary Compensation Table of each Eton Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Eton PharmaceuticalsPublic company · 4 yr
    • Chief Business Officer2022 – Present · 4 yrStock in role +1,113%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?